Browse diseases

…n adjuvant to enhance immune responses) have been conducted for NMIBC after BCG failure. Part of the results of the ADAPT-BLADDER tri…

…) estimates for female patients aged 40–90 years diagnosed with cervical cancer (aged 30–90 years), ovarian cancer, stomach cancer, bladder can…

…Background Bladder Cancer is the fourth most common cancer in men and a leading cause of …

…Background The use of immunologic agents to treat bladder cancer has been beneficial in both muscle-invasive and non-muscle inva…

…Background Bladder cancer is unique among visceral malignancies in that urine, which can …

…ng lymphocytes (TIL) has shown efficacy in malignancies such as melanoma, and preclinical data support this approach in bladder cancer. …

…revolutionized treatment outcomes for advanced cancers, notably melanoma, NSCLC, RCC, urothelial carcinoma, and HNSCC. 1 2 By antagonizi…

…n FGFR3 negative areas.Conclusions Our results indicate that in bladder cancer DC1/CD8+ T cell clustering is a key requirement for PD-1/PD-L1 …

…mune checkpoint inhibitors have shown limited response rates in bladder cancer. RC48-antibody-drug conjugate (ADC) shows potential for combina…

…d; the mean age was 67.6±13.6 years. The primary diagnoses were Renal Cell Carcinoma (31%), Bladder Cancer (31%), and Melanoma (38%). 65 patients (4…

…rs. The risks within 3 months of follow-up were as follows: for bladder cancer, the SIR was 33.69 (95% CI 32.02 to 35.43) in men and 30.00 (28…

…ia and presumed urinary tract infection owing to a pre-existing bladder cancer diagnosis. A urethral catheter was inserted on admission for mo…